Artemis Medicare Services Ltd
Artemis Medicare Services Ltd (AMSL) was incorporated on 2004, by the promoters of the Apollo Tyres Group, is engaged in healthcare business. AMSL operates a 541-bedded multi-specialty tertiary care hospital in Gurgaon. The specialty areas for AMSL include Orthopaedics, Oncology, Cardiovascular, Neurosciences and Bariatric & Minimally Invasive Surgery. ASML has been awarded with the NABH and JCI accreditation. AMSL has also diversified its presence through Artemis Daffodil , Artemis Lite, Artemis Cardiac Care and Artemis Solace models. [1][2]
- Market Cap ₹ 4,409 Cr.
- Current Price ₹ 320
- High / Low ₹ 324 / 141
- Stock P/E 67.9
- Book Value ₹ 57.9
- Dividend Yield 0.14 %
- ROCE 13.6 %
- ROE 11.4 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 5.53 times its book value
- Company has a low return on equity of 10.4% over last 3 years.
- Promoters have pledged 44.5% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Part of BSE Healthcare BSE Allcap BSE SmallCap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
217 | 261 | 368 | 402 | 459 | 503 | 547 | 563 | 402 | 545 | 714 | 845 | 879 | |
194 | 234 | 325 | 359 | 406 | 442 | 480 | 501 | 367 | 477 | 620 | 717 | 733 | |
Operating Profit | 23 | 27 | 43 | 43 | 53 | 60 | 66 | 62 | 35 | 68 | 94 | 128 | 145 |
OPM % | 10% | 11% | 12% | 11% | 11% | 12% | 12% | 11% | 9% | 12% | 13% | 15% | 17% |
2 | 1 | 3 | 5 | 4 | 3 | 2 | 4 | 7 | 3 | 7 | 7 | 15 | |
Interest | 15 | 13 | 12 | 9 | 9 | 9 | 11 | 13 | 12 | 11 | 19 | 30 | 31 |
Depreciation | 9 | 9 | 12 | 12 | 15 | 18 | 20 | 22 | 21 | 21 | 29 | 38 | 41 |
Profit before tax | 0 | 7 | 21 | 27 | 32 | 35 | 37 | 32 | 9 | 39 | 53 | 68 | 89 |
Tax % | 0% | 0% | 12% | 21% | 16% | 24% | 44% | 36% | 20% | 16% | 25% | 28% | |
0 | 7 | 19 | 22 | 27 | 27 | 21 | 20 | 7 | 33 | 40 | 49 | 65 | |
EPS in Rs | 0.02 | 0.32 | 0.88 | 1.03 | 1.29 | 1.27 | 0.98 | 1.54 | 0.54 | 2.46 | 2.96 | 3.62 | 4.75 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 15% | 12% |
Compounded Sales Growth | |
---|---|
10 Years: | 12% |
5 Years: | 9% |
3 Years: | 28% |
TTM: | 12% |
Compounded Profit Growth | |
---|---|
10 Years: | 22% |
5 Years: | 18% |
3 Years: | 98% |
TTM: | 45% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 111% |
1 Year: | 92% |
Return on Equity | |
---|---|
10 Years: | 10% |
5 Years: | 8% |
3 Years: | 10% |
Last Year: | 11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 0.00 | 13 | 13 | 13 | 13 | 14 | 14 |
Reserves | 109 | 116 | 135 | 163 | 183 | 210 | 280 | 301 | 308 | 348 | 393 | 438 | 783 |
118 | 110 | 85 | 68 | 94 | 91 | 114 | 108 | 137 | 190 | 268 | 305 | 307 | |
39 | 66 | 90 | 93 | 124 | 130 | 160 | 159 | 130 | 145 | 207 | 191 | 215 | |
Total Liabilities | 287 | 313 | 331 | 345 | 422 | 452 | 555 | 581 | 589 | 697 | 882 | 948 | 1,318 |
237 | 236 | 239 | 249 | 283 | 309 | 381 | 387 | 372 | 476 | 584 | 699 | 718 | |
CWIP | 0 | 0 | 0 | 1 | 27 | 43 | 49 | 56 | 81 | 64 | 95 | 33 | 44 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 6 | 12 | 15 | 15 |
50 | 77 | 91 | 94 | 112 | 100 | 124 | 137 | 132 | 152 | 192 | 200 | 541 | |
Total Assets | 287 | 313 | 331 | 345 | 422 | 452 | 555 | 581 | 589 | 697 | 882 | 948 | 1,318 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
22 | 45 | 53 | 20 | 58 | 72 | 41 | 56 | 27 | 61 | 129 | 108 | |
-5 | -12 | -10 | -14 | -74 | -67 | -50 | -22 | -34 | -106 | -153 | -89 | |
-18 | -21 | -35 | -24 | 19 | -10 | 14 | -33 | 13 | 44 | 30 | -27 | |
Net Cash Flow | -1 | 11 | 7 | -18 | 3 | -4 | 5 | 2 | 6 | -2 | 7 | -8 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 40 | 41 | 39 | 49 | 48 | 40 | 52 | 50 | 48 | 47 | 43 | 36 |
Inventory Days | 26 | 26 | 26 | 21 | 19 | |||||||
Days Payable | 144 | 237 | 195 | 189 | 187 | |||||||
Cash Conversion Cycle | -78 | -171 | -129 | -120 | -120 | 40 | 52 | 50 | 48 | 47 | 43 | 36 |
Working Capital Days | -9 | -70 | -59 | -31 | -44 | -53 | -26 | -28 | -15 | -10 | -29 | -17 |
ROCE % | 6% | 8% | 14% | 15% | 16% | 15% | 14% | 11% | 4% | 10% | 11% | 14% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Investor Presentation
15 Nov - Earnings Presentation - Q2 and H1 FY25
- Announcement under Regulation 30 (LODR)-Newspaper Publication 15 Nov
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
15 Nov - Artemis reports Q2 FY25 results with highest revenue.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
14 Nov - Monitoring Agency Report for Q2 FY2025 submitted.
-
Statement Of Deviation Or Variation- Quarter Ended September 30, 2024
14 Nov - No deviation in use of funds from preferential issue.
Geographical Revenue Break-up 9MFY24:[1]
Domestic : ~76%
Outside India : ~24%